JPX · 4564.T
OncoTherapy Science, Inc.
¥18+¥1 (+5.88%)
OncoTherapy Science, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.06% below the high.
Loading market information…
JPX · 2183.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Linical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 43.34% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Linical Co., Ltd.’s forward annual dividend is ¥8 per share, paid annual. The forward yield is 4.0% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Linical Co., Ltd.’s next earnings report is currently expected on Nov 13, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Linical Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Linical Co., Ltd., a global contract research organization provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariats; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥18+¥1 (+5.88%)
OncoTherapy Science, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.06% below the high.
¥403-¥16 (-3.82%)
J-Pharma Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.19% below the high.
¥89-¥3 (-3.26%)
Chiome Bioscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.56% below the high.
¥800-¥1 (-0.12%)
ADR120S, Inc.’s quoted price sits in the lower half of its reported 52-week range, 10.11% below the high.
¥701-¥6 (-0.85%)
StemCell Institute Inc.’s quoted price sits in the lower half of its reported 52-week range, 28.18% below the high.
¥135-¥1 (-0.74%)
TMS Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.18% below the high.
¥20-¥1 (-4.76%)
MEDINET Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.72% below the high.
¥40-¥1 (-2.44%)
BrightPath Biotherapeutics Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.33% below the high.
